| abstract |
PURPOSE: To obtain the subject preventive agent which contains bezafibrate as an active ingredient, gives the improvement of glucose content at stomach emptiness or after loading on the dietary test, and also lowers the triglyceride value and cholesterol value but they remain in the normal ranges. CONSTITUTION: Bezafibrate i.e., 2- 4-[2-(4-chlorobenzamide)-ethyl]phenoxy}-2- methylpropionic acid, which has been widely used for treatment of hyperlipemia is used as an active ingredient, and, when necessary, an additive insulin-emitting agent is admixed thereto. The dose is 200-600mg/day and the daily dose is preferably intaken between meals in the form of tablets or sugar-coated tablets. In the case that defective insulin secretion causes the diabetes, sulfonylurea, particularly an insulin emitter such as glibenclamide must be simultaneously given and both substance can be packed in a single dose unit. |